Dermatomyositis is a systemic autoimmune disease that manifests in the skin and muscles and can be divided into 6 subgroups according to the autoantibody profile (anti-TIF1-γ, anti-NXP2, anti-MDA5, anti-SAE (SUMO-1 activating enzyme), anti-Mi-2-associated and autoantibody-negative DM) with different prognoses [1]. Here, IFIH1 is linked to dermatomyositis.